{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T03:30:04Z","timestamp":1777433404997,"version":"3.51.4"},"reference-count":16,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2022,2,13]],"date-time":"2022-02-13T00:00:00Z","timestamp":1644710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100012188","name":"Pratt Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012188","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Australas Psychiatry"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Cariprazine is the third partial dopamine agonist now available in Australia. This paper will review the properties, evidence and likely clinical place of cariprazine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Cariprazine is a partial agonist with high affinity at dopamine D\n                      <jats:sub>2<\/jats:sub>\n                      and D\n                      <jats:sub>3<\/jats:sub>\n                      receptors, partial agonism at 5HT\n                      <jats:sub>1a<\/jats:sub>\n                      receptors, moderate 5HT\n                      <jats:sub>2a<\/jats:sub>\n                      and H\n                      <jats:sub>1<\/jats:sub>\n                      antagonism and no anticholinergic activity. It is rapidly absorbed, is unaffected by food, achieves a peak plasma level in 4\u20138 hours and has high bioavailability. The half-life of cariprazine and its metabolites is long (7\u20138\u00a0days); steady state occurs in 4\u20138 weeks. It is hepatically metabolized via 3A4 cytochrome enzymes. Cariprazine is an effective antipsychotic in acute schizophrenia in both short and longer placebo-controlled studies. Cariprazine appears to have small advantages in negative symptoms of schizophrenia. While not approved for bipolar disorder, cariprazine is effective in mania and mixed states but requires doses higher than current maximums recommended. Cariprazine causes more akathisia than aripiprazole or brexpiprazole but is less prone to insomnia, weight gain and sedation. Risks for hyperprolactinaemia and QT\n                      <jats:sub>c<\/jats:sub>\n                      prolongation are low. Cariprazine is another \u2018metabolically-friendly\u2019 antipsychotic for schizophrenia, with advantages for those with negative symptoms, mood symptoms or problems with adherence.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10398562211064254","type":"journal-article","created":{"date-parts":[[2022,2,13]],"date-time":"2022-02-13T21:34:41Z","timestamp":1644788081000},"page":"382-385","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Cariprazine: A new partial dopamine agonist with a familiar profile"],"prefix":"10.1177","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8119-6815","authenticated-orcid":false,"given":"Judy","family":"Hope","sequence":"first","affiliation":[{"name":"Eastern Health Clinical School, Monash University, Eastern Health Mental Health Program and Centre for Mental Health Education and Research at Delmont Private Hospital, Melbourne, VIC, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas A","family":"Keks","sequence":"additional","affiliation":[{"name":"Monash Medical Centre and Centre for Mental Health Education and Research at Delmont Private Hospital, Monash University, Melbourne, VIC, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,2,13]]},"reference":[{"key":"bibr1-10398562211064254","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852916000043"},{"key":"bibr2-10398562211064254","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00718-4"},{"key":"bibr3-10398562211064254","unstructured":"Geodon-Richter. REAGILA (Cariprazine) hard capsules, for oral use. Prescribing Information, approved 18 November 2020."},{"key":"bibr4-10398562211064254","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-016-0382-z"},{"key":"bibr5-10398562211064254","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2013.11.041"},{"key":"bibr6-10398562211064254","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.15m09997"},{"key":"bibr7-10398562211064254","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000346"},{"key":"bibr8-10398562211064254","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2016.06.030"},{"key":"bibr9-10398562211064254","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S301225"},{"key":"bibr10-10398562211064254","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30060-0"},{"key":"bibr11-10398562211064254","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.12238"},{"key":"bibr12-10398562211064254","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2014.11.018"},{"key":"bibr13-10398562211064254","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09081"},{"key":"bibr14-10398562211064254","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2017.08.040"},{"key":"bibr15-10398562211064254","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2015.15020164"},{"key":"bibr16-10398562211064254","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2018.18070824"}],"container-title":["Australasian Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10398562211064254","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10398562211064254","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10398562211064254","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:51:22Z","timestamp":1777377082000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10398562211064254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,13]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1177\/10398562211064254"],"URL":"https:\/\/doi.org\/10.1177\/10398562211064254","relation":{},"ISSN":["1039-8562","1440-1665"],"issn-type":[{"value":"1039-8562","type":"print"},{"value":"1440-1665","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,13]]}}}